PharmaEssentia Wins FDA Approval for BESREMi in ET
BURLINGTON, Mass., August 31, 2026 PharmaEssentia announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon...
ropeginterferon alfa-2b-njft
Advertisement
PharmaEssentia Secures FDA Approval for BESREMi Pen in Polycythemia Vera
BURLINGTON, Mass., June 26, 2026 PharmaEssentia USA Corporation announced that the U.S. Food and Drug Administration (FDA) has approved...
Advertisement
